A Phase IIA Study Evaluating the Efficacy of MK0457 as a 5-Day Continuous Infusion in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)

Trial Profile

A Phase IIA Study Evaluating the Efficacy of MK0457 as a 5-Day Continuous Infusion in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)

Discontinued
Phase of Trial: Phase II

Latest Information Update: 10 Oct 2014

At a glance

  • Drugs Tozasertib (Primary)
  • Indications Non-small cell lung cancer
  • Focus Therapeutic Use
  • Sponsors Merck Sharp & Dohme
  • Most Recent Events

    • 19 Nov 2007 Status changed from in progress to discontinued.
    • 06 Nov 2006 Status change
    • 08 Sep 2006 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top